Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
I'm PortAI, I can summarize articles.
Feb 7 (Reuters) - Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill. (Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments